ASH 2024 | Outcomes of inotuzumab/blinatumomab-based treatment in pts with Ph- ALL & myeloid-type mutations
In this video, Jayastu Senapati, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the outcomes of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) who possess myeloid-type mutations treated with frontline regimens containing inotuzumab and/or blinatumomab. Dr Senapati highlights that myeloid-type mutations may be associated with slightly inferior relapse-free survival and overall survival, but when treated with frontline immunotherapy-based regimens, these mutations do not necessarily lead to poor outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
